174 related articles for article (PubMed ID: 24866251)
1. Routine use of dual time ¹⁸F-FDG PET for staging of preoperative lung cancer: does it affect clinical management?
Shinozaki T; Utano K; Fujii H; Utano Y; Sasaki T; Kijima S; Kanazawa H; Kimura Y; Fujita A; Sugimoto H
Jpn J Radiol; 2014 Aug; 32(8):476-81. PubMed ID: 24866251
[TBL] [Abstract][Full Text] [Related]
2. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
3. [Value of (18)F-FDG PET-CT in the preoperative N staging of non-small cell lung cancer].
Li M; Wu N; Liang Y; Zheng R; Liu Y; Zhang WJ; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):288-92. PubMed ID: 19615286
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of 18F-2-deoxy-fluoro-D-glucose positron emission tomography for pN1 lymph nodes in patients with lung cancer.
Nakagawa M; Hara M; Sakurai K; Ozawa Y; Mizuno A; Tamaki T; Nishio M; Shibamoto Y
Acta Radiol; 2009 Jul; 50(6):638-44. PubMed ID: 19492198
[TBL] [Abstract][Full Text] [Related]
5. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
[TBL] [Abstract][Full Text] [Related]
6. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer.
Yamamoto Y; Nishiyama Y; Kimura N; Ishikawa S; Okuda M; Bandoh S; Kanaji N; Asakura M; Ohkawa M
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):236-45. PubMed ID: 17909790
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
8. Utility of high-definition FDG-PET image reconstruction for lung cancer staging.
Ozawa Y; Hara M; Shibamoto Y; Tamaki T; Nishio M; Omi K
Acta Radiol; 2013 Oct; 54(8):916-20. PubMed ID: 23761556
[TBL] [Abstract][Full Text] [Related]
9. Quantitative volumetric CT-histogram analysis in N-staging of 18F-FDG-equivocal patients with lung cancer.
Flechsig P; Kratochwil C; Schwartz LH; Rath D; Moltz J; Antoch G; Heussel CP; Rieser M; Warth A; Zabeck H; Kauczor HU; Haberkorn U; Giesel FL
J Nucl Med; 2014 Apr; 55(4):559-64. PubMed ID: 24525209
[TBL] [Abstract][Full Text] [Related]
10. [Significance of dual-time-point 18F-FDG PET imaging in evaluation of hilar and mediastinal lymph node metastasis in non-small-cell lung cancer].
Hu M; Yu JM; Liu NB; Liu LP; Guo HB; Yang GR; Zhang PL; Xu XQ
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):306-9. PubMed ID: 18788639
[TBL] [Abstract][Full Text] [Related]
11. Comparative Performance of ¹⁸F-FDG PET/MRI and ¹⁸F-FDG PET/CT in Detection and Characterization of Pulmonary Lesions in 121 Oncologic Patients.
Sawicki LM; Grueneisen J; Buchbender C; Schaarschmidt BM; Gomez B; Ruhlmann V; Wetter A; Umutlu L; Antoch G; Heusch P
J Nucl Med; 2016 Apr; 57(4):582-6. PubMed ID: 26742715
[TBL] [Abstract][Full Text] [Related]
12. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
13. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
14. Role of
Delgado Bolton RC; Calapaquí-Terán AK; Giammarile F; Rubello D
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(4):229-233. PubMed ID: 31202725
[TBL] [Abstract][Full Text] [Related]
15. Dual-time point
Park S; Paeng JC; Kang CH; Cheon GJ; Kang KW; Chung JK; Lee DS
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1317-1328. PubMed ID: 29502309
[TBL] [Abstract][Full Text] [Related]
16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
17. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
18. The clinical usefulness of F-18 FDG coincidence PET without attenuation correction and without whole-body scanning mode in pulmonary lesions comparison with CT, MRI, and clinical findings.
Kim S; Park CH; Han M; Hwang S; Lee C; Pai M
Clin Nucl Med; 1999 Dec; 24(12):945-9. PubMed ID: 10595474
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
Wu H; Dong S; Li X; Shi L; Shao D; Zhang Q; Chen M; Cao Y; Thant M; Huang X
Lung Cancer; 2020 Feb; 140():80-86. PubMed ID: 31901595
[TBL] [Abstract][Full Text] [Related]
20. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer.
Cermik TF; Mavi A; Basu S; Alavi A
Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):475-83. PubMed ID: 17957366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
